QLS31905 + QL1706

QLS31905 + QL1706 is a **combination therapy** that includes QLS31905 (specific details not identified in public sources) and QL1706. QL1706 is a bifunctional antibody mixture produced using the MabPair platform, containing anti-PD-1 IgG4 (iparomlimab) and anti-CTLA-4 IgG1 (tuvonralimab) antibodies in a fixed ratio. QL1706 exerts dual immune checkpoint blockade by inhibiting both the PD-1 and CTLA-4 pathways, leading to enhanced T-cell mediated antitumor responses. This dual blockade has demonstrated promising efficacy and safety across multiple solid tumors including NSCLC, cervical cancer, and small cell lung cancer. The platform allows fine-tuning of each antibody component for optimal target coverage and safety. QLS31905's mechanism, structure, class, and developer are not publicly characterized in currently available sources.